Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;65(2):222-225.
doi: 10.1111/myc.13390. Epub 2021 Dec 3.

Laboratory-based surveillance of Candida auris in Colombia, 2016-2020

Patricia Escandón  1 , Diego H Cáceres  2   3 , Diana Lizarazo  1 , Shawn R Lockhart  2 , Meghan Lyman  2 , Carolina Duarte  1
Affiliations

Laboratory-based surveillance of Candida auris in Colombia, 2016-2020

Patricia Escandón et al. Mycoses. 2022 Feb.

Abstract

Background: Since the first report of Candida auris in 2016, the Colombian Instituto Nacional de Salud (INS) has implemented a national surveillance of the emerging multidrug-resistant fungus.

Objectives: This report summarises the findings of this laboratory-based surveillance from March 2016 to December 2020.

Results: A total of 1720 C. auris cases were identified, including 393 (23%) colonisation cases and 1327 (77%) clinical cases. Cases were reported in 20 of 32 (62%) departments of Colombia and involved hospitals from 33 cities. The median age of patients was 34 years; 317 (18%) cases were children under 16 years, 54% were male. The peak number of cases was observed in 2019 (n = 541). In 2020, 379 (94%) of 404 cases reported were clinical cases, including 225 bloodstream infections (BSI) and 154 non-BSI. Among the 404 cases reported in 2020, severe COVID-19 was reported in 122 (30%). Antifungal susceptibility was tested in 379 isolates. Using CDC tentative breakpoints for resistance, 35% of isolates were fluconazole resistant, 33% were amphotericin B resistant, and 0.3% isolates were anidulafungin resistant, 12% were multidrug resistant, and no pan-resistant isolates were identified.

Conclusion: For five years of surveillance, we observed an increase in the number and geographic spread of clinical cases and an increase in fluconazole resistance. These observations emphasise the need for improved measures to mitigate spread.

Keywords: Candida auris; COVID-19; Colombia; SARS-CoV-2; bloodstream infection; laboratory surveillance.

PubMed Disclaimer

Conflict of interest statement

All authors report no potential conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the funding agencies.

Figures

FIGURE 1
FIGURE 1
Confirmed cases of Candida auris in Colombia, 2016–2020
See this image and copyright information in PMC

References

    1. INS . Alerta de C. auris ‐ Instituto Nacional de Salud; 2016. Disponible en: http://www.ins.gov.co/tramites‐y‐servicios/examenes‐de‐inter%C3%A9s‐en‐s...
    1. Caceres DH, Forsberg K, Welsh RM, et al. Candida auris: A review of recommendations for detection and control in healthcare settings. J Fungi (Basel). 2019;5(4):111. - PMC - PubMed
    1. Forsberg K, Woodworth K, Walters M, et al. Candida auris: The recent emergence of a multidrug‐resistant fungal pathogen. Med Mycol. 2019;57(1):1‐12. - PubMed
    1. CLSI . M60 Performance Standards for Antifungal Susceptibility Testing of Yeasts, 1st Edition 2017. Available from: https://clsi.org/
    1. (CDC) CfDCaP . Recommendations for Identification of Candida auris ; 2018. Available from: https://www.cdc.gov/fungal/candida‐auris/recommendations.html